2022, Volume 13, Issue 6
Engineering >> 2022, Volume 13, Issue 6 doi: 10.1016/j.eng.2021.07.021
Factors Predicting Progression to Severe COVID-19: A Competing Risk Survival Analysis of 1753 Patients in Community Isolation in Wuhan, China
a Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
b Heidelberg Institute of Global Health (HIGH), Faculty of Medicine and University Hospital, Heidelberg University, Heidelberg 69117, Germany
c Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
d Department of Pulmonary and Critical Care Medicine, Beijing Hospital, Beijing 100730, China
e National Center of Gerontology,Institute of Geriatric Medicine, Beijing 100730, China
f Division of Primary Care and Population Health, Department of Medicine, Stanford University, Stanford, CA 94305, USA
g Peking Union Medical College Hospital, Beijing 100730, China
h State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
i National Clinical Research Center for Respiratory Diseases, Beijing 100029, China
j Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China–Japan Friendship Hospital, Beijing 100029, China
# These authors contributed equally to this work.
Next Previous
Abstract
Current knowledge of the risk factors predicting the progression to severe coronavirus disease 2019 (COVID-19) among patients in community isolation who either are asymptomatic or only suffer from mild COVID-19 is very limited. Using a multivariable competing risk survival analysis, we herein identify several important predictors of progression to severe COVID-19—rather than to recovery—among patients in community isolation. A competing risk survival analysis was performed on time-to-event data from a cohort study of all COVID-19 patients (n = 1753) in the largest community isolation center in Wuhan, China, from opening to closing. The exposures were age, sex, respiratory symptoms, gastrointestinal symptoms, general symptoms, and computed tomography (CT) scan signs. The main outcomes were time to COVID-19 deterioration or recovery. The factors predicting progression to severe COVID-19 among the patients in community isolation were: male sex (hazard ratio (HR) = 1.29, 95% confidence interval (CI), 1.04–1.58, p = 0.018), young and old age, dyspnea (HR = 1.58, 95% CI, 1.24–2.01, p < 0.001), and CT signs of ground-glass opacity (HR = 1.39, 95% CI, 1.04–1.86, p = 0.024) and infiltrating shadows (HR= 1.84, 95% CI, 1.22–2.78, p = 0.004). The risk of progression was found to be lower among patients with nausea or vomiting (HR = 0.53, 95% CI, 0.30–0.96, p = 0.036) and headaches (HR = 0.54, 95% CI, 0.29–0.99, p = 0.046). Based on the results of this study, resource-poor settings, dyspnea, sex, and age can easily be used to identify mild COVID-19 patients who are at increased risk of progression. Looking for CT signs of ground-glass opacity and infiltrating shadows may be an affordable option to support triage decisions in resource-rich settings. Common and unspecific symptoms including headaches, nausea, and vomiting likely induced the selection for community isolation of COVID-19 patients who were relatively unlikely to deteriorate. Triage and prioritization outcomes could be boosted if strategies are incorporated to minimize the inefficient prioritization of harmless comorbidities.
Keywords
COVID-19 ; Asymptomatic and mild ; Facility-based isolation ; Fangcang shelter hospital ; Competing risk survival analysis
SupplementaryMaterials
Figures
Fig. 1
Fig. 2
Fig. 3
References
[ 1 ] Nelson B. Too little or too much? Missing the Goldilocks zone of hospital capacity during COVID-19. BMJ 2020;369:m2332. link1
[ 2 ] Haroon S, Chandan JS, Middleton J, Cheng KK. COVID-19: breaking the chain of household transmission. BMJ 2020;370:m3181. link1
[ 3 ] Wilder-Smith A, Cook AR, Dickens BL. Institutional versus home isolation to curb the COVID-19 outbreak—authors’ reply. Lancet 2020;396(10263):1632–3. link1
[ 4 ] Chen S, Chen Q, Yang J, Lin L, Li L, Jiao L, et al. Curbing the COVID-19 pandemic with facility-based isolation of mild cases: a mathematical modeling study. J Travel Med 2020;28(2):taaa226. link1
[ 5 ] Chen S, Zhang Z, Yang J, Wang J, Zhai X, Bärnighausen T, et al. Fangcang shelter hospitals: a novel concept for responding to public health emergencies. Lancet 2020;395(10232):1305–14. link1
[ 6 ] The Atlantic. What’s behind South Korea’s COVID-19 exceptionalism [Internet]. The Atlantic Monthly Group; [updated 2020 May 6; cited 2020 May 14]. Available from: https://www.theatlantic.com/ideas/archive/2020/05/ whats-south-koreas-secret/611215/. link1
[ 7 ] Her M. Repurposing and reshaping of hospitals during the COVID-19 outbreak in South Korea. One Health 2020;10:100137. link1
[ 8 ] Chia ML, Him Chau DH, Lim KS, Yang Liu CW, Tan HK, Tan YR. Managing COVID-19 in a novel, rapidly deployable community isolation quarantine facility. Ann Intern Med 2021;174(2):247–51. link1
[ 9 ] Towards Data Science. COVID-19—what do we know about the situation in Vietnam? [Internet]. [updated 2020 May 2; cited 2020 Nov 13]. Available from: https://towardsdatascience.com/covid-19-what-do-we-know-about-thesituation-in-vietnam-82c195163d7e. link1
[10] Chen S, Yang J, Yang W, Wang C, Bärnighausen T. COVID-19 control in China during mass population movements at New Year. Lancet 2020;395 (10226):764–6. link1
[11] Centers for Disease Control and Prevention. Operational considerations for community isolation centers for COVID-19 in low-resource settings [Internet]. Washington, DC: US Department of Health & Human Services; [updated 2020 Aug 19; cited 2020 Sep 29]. Available from: https://www.cdc.gov/coronavirus/ 2019-ncov/global-covid-19/operational-considerations-isolation-centers.html. link1
[12] World Health Organization. Operational considerations for case management of COVID-19 in health facility and community. Interim guidance. Pediatria i Med Rodz 2020;16(1):27–32. link1
[13] Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of COVID-19— studies needed. N Engl J Med 2020;382(13):1194–6. link1
[14] Goh KJ, Choong MC, Cheong EH, Kalimuddin S, Wen SD, Phua GC, et al. Rapid progression to acute respiratory distress syndrome: review of current understanding of critical illness from COVID-19 infection. Ann Acad Med Singap 2020;49(1):1–9. link1
[15] Greenhalgh T, Koh GCH, Car J. COVID-19: a remote assessment in primary care. BMJ 2020;368:m1182. link1
[16] Li M, Lei P, Zeng B, Li Z, Yu P, Fan B, et al. Coronavirus disease (COVID-19): spectrum of CT findings and temporal progression of the disease. Acad Radiol 2020;27(5):603–8. link1
[17] Yousefzadegan S, Rezaei N. Case report: death due to novel coronavirus disease (COVID-19) in three brothers. Am J Trop Med Hyg 2020;102 (6):1203–4. link1
[18] Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet 2020;395 (10231):1225–8. link1
[19] Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study. Lancet Respir Med 2020;8 (5):475–81. link1
[20] Vincent JL, Taccone FS. Understanding pathways to death in patients with COVID-19. Lancet Respir Med 2020;8(5):430–2. link1
[21] Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect 2020;80(5):e1–6. link1
[22] Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect 2020;80(6):639–45. link1
[23] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180(7):934–43. link1
[24] Liang W, Liang H, Ou L, Chen B, Chen A, Li C et al.; China Medical Treatment Expert Group for COVID-19. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med 2020;180(8):1081–9. link1
[25] Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV et al.; Asian Critical Care Clinical Trials Group. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med 2020;8 (5):506–17. link1
[26] Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J 2020;133(9):1032–8. link1
[27] Liang WH, Guan WJ, Li CC, Li YM, Liang HR, Zhao Y, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei and outside Hubei: a nationwide analysis of China. Eur Respir J 2020;55(6):2000562. link1
[28] Wang X, Fang J, Zhu Y, Chen L, Ding F, Zhou R, et al. Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang hospital. Clin Microbiol Infect 2020;26(8):1063–8. link1
[29] Liao Y, Feng Y, Wang B, Wang H, Huang J, Wu Y, et al. Clinical characteristics and prognostic factors of COVID-19 patients progression to severe: a retrospective, observational study. Aging 2020;12(19):18853–65. link1
[30] Wang X. Mainland medics banking on experience to help HK fight COVID-19 [Internet]. Beijing: China Daily Information Co.; c1995–2021 [updated 2020 Aug 3; cited 2020 Aug 4]. Available online: https://www.chinadaily.com.cn/a/ 202008/03/WS5f27ad72a31083481725dd2e.html. link1
[31] The Lancet. Sustaining containment of COVID-19 in China. Lancet 2020;395 (10232):1230. link1
[32] Gilbert M, Dewatripont M, Muraille E, Platteau JP, Goldman M. Preparing for a responsible lockdown exit strategy. Nat Med 2020;26(5):643–4. link1
[33] Petersen E, Wasserman S, Lee SS, Go U, Holmes AH, Al-Abri S, et al. COVID-19— we urgently need to start developing an exit strategy. Int J Infect Dis 2020;96 (96):233–9. link1
[34] Chen S, Chen Q, Yang W, Xue L, Liu Y, Yang J, et al. Buying time for an effective epidemic response: the impact of a public holiday for outbreak control on COVID-19 epidemic spread. Engineering 2020;6(10):1108–14. link1
[35] National Health Commission of the People’s Republic of China. Manual for working in Fangcang shelter hospitals (3rd edition) [Internet]. Beijing: National Health Commission of the People’s Republic of China; [updated 2020 Feb 22; cited 2020 Feb 24]. Available from: https://mp.weixin.qq.com/ s/va9vs4HuP8wRQM5fALQcrg.Chinese. link1
[36] Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94(446):496–509. link1
[37] Wolbers M, Koller MT, Stel VS, Schaer B, Jager KJ, Leffondré K, et al. Competing risks analyses: objectives and approaches. Eur Heart J 2014;35(42):2936–41. link1
[38] Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol 2009;170(2):244–56. link1
[39] Hosmer DW, Lemeshow S, May S. Applied survival analysis: regression modeling of time to event data. New York: Wiley; 2002. link1
[40] McCaw ZR, Tian L, Vassy JL, Ritchie CS, Lee CC, Kim DH, et al. How to quantify and interpret treatment effects in comparative clinical studies of COVID-19. Ann Intern Med 2020;173(8):632–7. link1
[41] Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982;69(1):239–41. link1
[42] Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med 2017;36(27):4391–400. link1
[43] Prettner K, Chen S, Kuhn M, Bloom DE. Effective pandemic management that minimises economic harm [Internet]. [updated 2021 Jan 4; cited 2021 Jan 22]. Available from: https://voxeu.org/article/effective-pandemic-managementminimises-economic-harm. link1
[44] Chen S, Prettner K, Kuhn M, Bloom DE. The economic burden of COVID-19 in the United States: estimates and projections under an infection-based herd immunity approach. J Econ Ageing 2021;20:100328. link1
[45] Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146(1):110–8. link1
[46] Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism 2020;108:154262. link1
[47] Xie J, Covassin N, Fan Z, Singh P, Gao W, Li G, et al. Association between hypoxemia and mortality in patients with COVID-19. Mayo Clin Proc 2020;95 (6):1138–47. link1
[48] Cecconi M, Piovani D, Brunetta E, Aghemo A, Greco M, Ciccarelli M, et al. Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for COVID-19 infection in Lombardy, Italy. J Clin Med 2020;9(5):1548. link1
[49] Yuan M, Yin W, Tao Z, Tan W, Hu Y. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. PLoS ONE 2020;15(3):e0230548. link1
[50] Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS et al.; Predictors of COVID-19 severity: a literature review. Rev Med Virol 2021;31(1):1–10. link1
[51] Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J et al.; Yale IMPACT Research Team. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 2020;588(7837):315–20. link1
[52] Uygun Ö, Ertas M, Ekizog˘lu E, Bolay H, Özge A, Kocasoy Orhan E, et al. Headache characteristics in COVID-19 pandemic—a survey study. J Headache Pain 2020;21(1):121. link1
[53] Yu F, Geldsetzer P, Meierkord A, Yang J, Chen Q, Jiao L, et al. Knowledge about coronavirus disease 2019 among adults in China: a cross-sectional online survey. J Med Internet Res 2021;23(4):e26940. link1
[54] Li J, Chen Z, Nie Y, Ma Y, Guo Q, Dai X. Identification of symptoms prognostic of COVID-19 severity: multivariate data analysis of a case series in Henan Province. J Med Internet Res 2020;22(6):e19636. link1
[55] Pan XF, Yang J, Wen Y, Li N, Chen S, Pan A. Non-communicable diseases during the COVID-19 pandemic and beyond. Engineering 2021;7(7):899–902.
[56] Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of smoking on COVID-19 severity: a systematic review and meta-analysis. J Med Virol 2021;93(2):1045–56. link1
[57] Chen S, Kuhn M, Prettner K. Tobacco control policies: the authors reply. Health Aff 2020;39(2):346. link1
[58] Chen S, Kuhn M, Prettner K, Bloom DE. Noncommunicable diseases attributable to tobacco use in China: macroeconomic burden and tobacco control policies. Health Aff 2019;38(11):1832–9. link1
京公网安备 11010502051620号
